Sera (SERA)
Develops blood tests and predictive analytics for earlier assessment of spontaneous preterm-birth risk.
Something off on this page? Send us feedback.
Develops and commercializes the PreTRM blood test for assessing spontaneous preterm-birth risk in singleton pregnancies. Its pregnancy-focused platform combines proteomics, bioinformatics, clinical testing, data, and economic analysis; commercial adoption depends on payer coverage and clinical use.
PreTRM is a non-invasive blood test for assessing spontaneous preterm-birth risk in singleton pregnancies. It is the first commercial product within a pregnancy-focused pipeline of biomarker tests and predictive analytic products.
The platform combines proteomics, bioinformatics, clinical testing, data, and economic analysis to support pregnancy care. Its stated mission is to give pregnant women, physicians, and payers actionable information for maternal and neonatal health. Operations include a CLIA-certified laboratory in Salt Lake City.
Commercial execution centers on payer discussions and converting clinical evidence into broader adoption and coverage. Payer coverage and clinical use shape the commercial path.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jun 4, 2026 | Craig-Hallum | Target | Target: — | Target: $6 |
| Dec 14, 2025 | Jefferies | Target | Target: — | Target: $5 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $46.4M · Total debt $3.0M · Total assets $86.7M · Shareholders' equity $59.4M
- Revenue
- $30.0K
- Operating income
- −$10.0M
- Net income
- −$9.1M
No dividends on record.
| Institutions | 43.24% | 17.06M shares | |
|---|---|---|---|
| 46 holders · as of Jun 30, 2026 | |||
| Insiders | 8.05% | 3.17M shares | |
| 17 holders · as of Sep 11, 2026 | |||
| Strategic holders | 6.98% | 2.75M shares | |
| 1 holder · as of Jul 15, 2026 | |||
| Other | 41.73% | 16.47M shares | |
| remainder | |||
39.45M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Baker Bros. Advisors LPInstitution | 13.94% | 5.50M A | as of Jun 30, 2026 |
Whetstone Capital Advisors, LLCInstitution | 8.38% | 3.31M A | as of Jun 30, 2026 |
Abrdn PLCInstitution | 6.98% | 2.75M A | as of Jun 30, 2026 |
Aberdeen Group plcStrategic | 6.98% | 2.75M | filed Jul 15, 2026 |
Domain Partners VIII, L.P.Institution | 6.40% | 2.52M | filed Jan 4, 2022 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 10, 2026 | Benjamin Jackson | officer: General Counsel | −2,190 | $2.00 |
| Sep 10, 2026 | Tiffany Eul Davis Inglis | officer: Chief Medical Officer | −486 | $2.00 |
| Sep 10, 2026 | Zhenya Lindgardt | director, officer: Chief Executive Officer | −7,022 | $2.00 |
| Sep 10, 2026 | Dyaarl Lee Jr. Anderson | officer: Chief Commercial Officer | −1,800 | $2.00 |
| Sep 8, 2026 | Zhenya Lindgardt | director, officer: Chief Executive Officer | −20,139 | $2.00 |
- Natera
Prenatal blood-based screening through Panorama NIPT
- Myriad Genetics
Prenatal screening portfolio led by Prequel and FirstGene
- Quest Diagnostics
QNatal Advanced prenatal genetic screening through a national lab
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Sera | $2.16 | +1.89% | $81.0M | — | — | 1,156.6 | +76.5% |
| Natera | $390.69 | +5.41% | $53.08B | — | — | 19.6 | +37.7% |
| Myriad Genetics | $3.97 | −0.95% | $378.7M | — | — | 0.5 | −10.5% |
| Quest Diagnostics | $236.30 | −3.50% | $27.03B | 26.0 | 20.6 | 2.3 | +10.2% |
| Median | 26.0 | 20.6 | 2.3 | +10.2% |